Identification of Mechanisms of Acquired Resistance to Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)

被引：12

作者：

Elamin, Y. ^{[1
]}

Robichaux, J. ^{[2
]}

Carter, B. ^{[3
]}

Altan, M. ^{[2
]}

Gibbons, D. ^{[1
]}

Fossella, F. ^{[4
]}

Simon, G. ^{[1
]}

Lam, V. ^{[1
]}

Blumenschein, G., Jr. ^{[2
]}

Tsao, A. ^{[1
]}

Kurie, J. ^{[2
]}

Mott, F. ^{[1
]}

Negrao, M. ^{[1
]}

Hu, L. ^{[2
]}

He, J. ^{[2
]}

Nilsson, M. ^{[2
]}

Roeck, B. ^{[5
]}

Yang, Z. ^{[5
]}

Papadimitrakopoulou, V. ^{[1
]}

Heymach, J. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Diagnost Radiol Thorac Imaging, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Thorac & Cardiovasc Surg, Houston, TX 77030 USA

[5] Spectrum Pharmaceut, Irvine, CA USA

来源：

关键词：

EGFR exon 20 insertion; Targeted therapy;

D O I：

10.1016/j.jtho.2019.08.567

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA09.03

引用

页码：S282 / S283

页数：2